Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Metha Apiwattanakul

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Journal of the Neurological Sciences|July 18, 2016
Concurrent anterior and posterior visual pathway impairment in a patient treated with infliximabSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|April 17, 2015
NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: A cross sectional studyMetha Apiwattanakul, Chayut Kasemsuk
Multiple Sclerosis and Related Disorders|April 22, 2017
Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literatureSaharat Aungsumart, Metha Apiwattanakul
Plos One|February 13, 2020
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysisSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|March 31, 2023
Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysisSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|February 15, 2025
Impact of COVID-19 and vaccination on multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)Metha Apiwattanakul, Chawarat Ounmuang, Saharat Aungsumart
Neuro-Ophthalmology (Aeolus Press)|October 5, 2020
Case Report: Anti-myelin Oligodendrocyte Glycoprotein (MOG) Positive in a Patient Presented with Orbital Apex SyndromeSireedhorn Kurathong, Anoma Sanpatchayapong, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|January 23, 2026
Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG-positive NMOSD patients: A retrospective cohort studyChayangkoon Siripornmongkol, Metha Apiwattanakul, Saharat Aungsumart
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 29, 2018
Abnormal level of consciousness predicts outcomes of patients with anti-NMDA encephalitisSaharat Aungsumart, Atina Ha, Metha Apiwattanakul
Journal of Neuroimmunology|May 22, 2026
Clinical features and treatment response of anti-Neurofascin 155 antibody-positive neuropathy in neurological Institute of ThailandNarupat Suanprasert, Chaichana Sinthuwong, Metha Apiwattanakul, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Journal of the Neurological Sciences|July 18, 2016
Concurrent anterior and posterior visual pathway impairment in a patient treated with infliximabSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|April 17, 2015
NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: A cross sectional studyMetha Apiwattanakul, Chayut Kasemsuk
Multiple Sclerosis and Related Disorders|April 22, 2017
Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literatureSaharat Aungsumart, Metha Apiwattanakul
Plos One|February 13, 2020
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysisSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|March 31, 2023
Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysisSaharat Aungsumart, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|February 15, 2025
Impact of COVID-19 and vaccination on multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)Metha Apiwattanakul, Chawarat Ounmuang, Saharat Aungsumart
Neuro-Ophthalmology (Aeolus Press)|October 5, 2020
Case Report: Anti-myelin Oligodendrocyte Glycoprotein (MOG) Positive in a Patient Presented with Orbital Apex SyndromeSireedhorn Kurathong, Anoma Sanpatchayapong, Metha Apiwattanakul
Multiple Sclerosis and Related Disorders|January 23, 2026
Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG-positive NMOSD patients: A retrospective cohort studyChayangkoon Siripornmongkol, Metha Apiwattanakul, Saharat Aungsumart
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 29, 2018
Abnormal level of consciousness predicts outcomes of patients with anti-NMDA encephalitisSaharat Aungsumart, Atina Ha, Metha Apiwattanakul
Journal of Neuroimmunology|May 22, 2026
Clinical features and treatment response of anti-Neurofascin 155 antibody-positive neuropathy in neurological Institute of ThailandNarupat Suanprasert, Chaichana Sinthuwong, Metha Apiwattanakul, et al.
Pageof 5